Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how long-term LEAP-002 data provides critical reassurance around Lenvima’s durability and safety in treating ...

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how consistent survival data from the LEAP-002 study reaffirms lenvatinib’s value in first-line treatment of ...

The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association ...

Eisai Pharma is set to establish a new Global Capability Center (GCC) in Visakhapatnam, aiming to boost its digital ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value for money”.

Japanese drugmaker Eisai today revealed that it has launched its Urece (dotinurad) in China as a treatment for gout. Urece ...

Eisai Pharma, a noted human health care pharmaceutical company with a global presence, announced its plans to establish a new ...

Eisai Europe’s headquarters were expanded to become Eisai Europe, Middle East, Africa and Russia in March 2012. Gary joined Eisai in 2008 as European Commercial Development Director.

The Bioindustry Award, now marking its 9th year, recognizes achievements that have significantly contributed to the development of the bioindustry or are expected to contribute to its future growth.

Visakhapatnam: Eisai Pharma, a noted human health care pharmaceutical company, announced its plans to establish a new global ...

Japanese authorities are putting Eisai (TYO: 4523) under pressure to reconsider the price of its Alzheimer’s disease therapy ...